SCRIBE THERAPEUTICS Trademark

Trademark Overview


On Friday, May 20, 2022, a trademark application was filed for SCRIBE THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the SCRIBE THERAPEUTICS trademark a serial number of 97420511. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Monday, December 15, 2025. This trademark is owned by Scribe Therapeutics Inc.. The SCRIBE THERAPEUTICS trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical and biological preparations based on genetic engineering and gene therapy for use in prevention, and treatment of diseases in human therapeutics, namely, diseases caused by genetic mutations and diseases and disorders for which gene modification would ameliorate or cure; Gene therapy products, namely, biological preparations based on engineered cells for medical use for the treatment of diseases caused by genetic mutations and of diseases and disorders for which gene modification would ameliorate or cure related to immuno-oncology, degenerative disorders, traumatic injury, enzyme replacement therapy, and immunology; Pharmaceutical and biological preparations based on gene, genome, and cellular editing, modulation, and modification for use in human therapeutics, namely, for the prevention, and treatment of diseases caused by genetic mutations and of diseases and disorders for which gene modification would ameliorate or cure; Pharmaceutical preparations, namely, therapeut...

Scientific and medical research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic transcriptional regulation, genetic transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering research and development of pharmaceuticals, biological preparations, and therapeutic products and services; Design and development of engineered cells for use in scientific research and in drug discovery and development; Providing medical and scientific research information in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic transcriptional regulation, genetic transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering; Molecular diagnostic services in the nature of genetic testing for medical research purposes
scribe therapeutics

General Information


Serial Number97420511
Word MarkSCRIBE THERAPEUTICS
Filing DateFriday, May 20, 2022
Status734 - FIFTH EXTENSION - GRANTED
Status DateMonday, December 15, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 25, 2023

Trademark Statements


NOT AVAILABLE"THERAPEUTICS"
Goods and ServicesPharmaceutical and biological preparations based on genetic engineering and gene therapy for use in prevention, and treatment of diseases in human therapeutics, namely, diseases caused by genetic mutations and diseases and disorders for which gene modification would ameliorate or cure; Gene therapy products, namely, biological preparations based on engineered cells for medical use for the treatment of diseases caused by genetic mutations and of diseases and disorders for which gene modification would ameliorate or cure related to immuno-oncology, degenerative disorders, traumatic injury, enzyme replacement therapy, and immunology; Pharmaceutical and biological preparations based on gene, genome, and cellular editing, modulation, and modification for use in human therapeutics, namely, for the prevention, and treatment of diseases caused by genetic mutations and of diseases and disorders for which gene modification would ameliorate or cure; Pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders, namely, neurological disorders, Huntington's disease, amyotrophic lateral sclerosis (ALS), front temporal dementia, Alzheimer's, Parkinson's, ataxia, autism, epilepsy, and pain, and also for the prevention and treatment of cardiovascular, peripheral nervous system, endocrine, gastrointestinal, renal, genetic immunological, hepatic, infectious, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, respiratory, urogenital, urological, and hematologic diseases and disorders, and cancer
Goods and ServicesScientific and medical research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic transcriptional regulation, genetic transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering research and development of pharmaceuticals, biological preparations, and therapeutic products and services; Design and development of engineered cells for use in scientific research and in drug discovery and development; Providing medical and scientific research information in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic transcriptional regulation, genetic transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering; Molecular diagnostic services in the nature of genetic testing for medical research purposes

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, May 25, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, May 25, 2022
Primary Code042
First Use Anywhere DateThursday, October 1, 2020
First Use In Commerce DateThursday, October 1, 2020

Trademark Owner History


Party NameScribe Therapeutics Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressAlameda, CA 94501

Party NameScribe Therapeutics Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressAlameda, CA 94501

Trademark Events


Event DateEvent Description
Tuesday, May 24, 2022NEW APPLICATION ENTERED
Wednesday, May 25, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, March 9, 2023ASSIGNED TO EXAMINER
Thursday, March 16, 2023EXAMINERS AMENDMENT -WRITTEN
Thursday, March 16, 2023EXAMINERS AMENDMENT E-MAILED
Thursday, March 16, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, March 16, 2023EXAMINER'S AMENDMENT ENTERED
Thursday, March 16, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 5, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 25, 2023PUBLISHED FOR OPPOSITION
Tuesday, April 25, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 20, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sunday, December 10, 2023SOU TEAS EXTENSION RECEIVED
Sunday, December 10, 2023SOU EXTENSION 1 FILED
Sunday, December 10, 2023SOU EXTENSION 1 GRANTED
Tuesday, December 12, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 11, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, June 11, 2024SOU EXTENSION 2 FILED
Tuesday, June 11, 2024SOU EXTENSION 2 GRANTED
Thursday, June 13, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sunday, December 15, 2024SOU TEAS EXTENSION RECEIVED
Sunday, December 15, 2024SOU EXTENSION 3 FILED
Sunday, December 15, 2024SOU EXTENSION 3 GRANTED
Monday, March 3, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 18, 2025SOU TEAS EXTENSION RECEIVED
Tuesday, December 9, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, June 18, 2025SOU EXTENSION 4 FILED
Tuesday, December 9, 2025SOU EXTENSION 4 GRANTED
Tuesday, December 9, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sunday, December 14, 2025SOU TEAS EXTENSION RECEIVED
Sunday, December 14, 2025SOU EXTENSION 5 FILED
Monday, December 15, 2025SOU EXTENSION 5 GRANTED
Monday, December 15, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED